We have recently demonstrated a similar increment of 17βHSD1 following aromatase inhibitor (exemestane) treatment in the group associated with decreased Ki67 labeling index or clinical responders in breast cancer patients [27]. This evidence concerns the gene MKI67 and breast carcinoma.